Under the direction of Dr. Michael Houghton, a world leader in the HCV and vaccine fields for almost three decades, the AVI team of specialists is developing a vaccine against Hepatitis C. Although Hepatitis C can now be treated, there is no vaccine to prevent the infection. Furthermore, due to the high cost of the drugs, and the potential for reoccurrence after treatment, there is still a high unmet need for a prophylactic vaccine, especially in countries with high incidences of infection.
The team has designed a novel vaccine and is currently manufacturing it under high-quality GMP conditions for human use. GMP production is a result of the association of the AVI with the Alberta Cell Therapy Manufacturing (ACTM), both at the University of Alberta. Phase I clinical trials are expected to start mid to late 2019.